Jacky (Jiajie) Li is a partner at Global Law Office, based in Shanghai. He is an attorney-at-law in the PRC and California, US, and is a US ACFE certified fraud examiner and a contributing expert for the United Kingdom’s The Law Reviews. He mainly focuses on regulatory compliance, corporate and government investigations, dispute resolution and litigation, healthcare and life sciences.

Jacky Li has practised in regulatory compliance for more than 15 years and has extensive experience. He is well versed in conducting various types of internal investigations and dealing with government investigations, in connection with anti-corruption (including US FCPA), anti-monopoly and anti-money laundering matters, white-collar crime, cybersecurity and data compliance. He provides a full range of legal and compliance services to many large multinational companies, and state-owned and privately owned enterprises, and he has represented companies in dealings with cross-jurisdictional government authorities.

In addition, Jacky Li has been publishing over 10 academic journals and more than 50 articles to support the development of the industry. Notably, Jacky Li was invited by the China Council for the Promotion of International Trade Commercial Legal Service Center and China Pharmaceutical Industry Association in 2022 as an expert to draft and edit the Guidance Books for Corporate Compliance Practitioner Professional Training and Pharmaceutical Industry Compliance Management Practice, introducing practical guidelines on dealing with internal and external compliance & regulatory investigations for China compliance officers, making the industry’s first. He also serves as a standing member of the Law and Compliance Committee of the Shanghai Bar Association and a director of the Association of China Compliance Professionals (ACCP). Jacky Li lectures on law and compliance-related practice courses for postgraduates.

Prior to joining Global Law Office, Jacky Li worked at the legal affairs department of the Shanghai Municipal Public Security Bureau, where he obtained extensive judicial experience and practical first-hand knowledge of criminal investigations and administrative enforcement as well as formulation of regulations and policies. Jacky Li also worked at a renowned US law firm in cross-border compliance practice.

PRC Licensed Lawyer

U.S. California Licensed Lawyer

US ACFE Certified Fraud Examiner

LL.M. East China University of Political Science and Law

BA East China University of Political Science and Law

Jacky Li has received numerous awards from prestigious global legal ranking institutions. Jacky Li has been ranked by The Legal 500 both as a Next Generation Partner and as a Rising Star for regulatory compliance practice in 2020-2023, and he was also noted as a recommended lawyer for healthcare practice in 2019-2023. Jacky Li has been ranked as an Up and Coming Lawyer in Corporate Investigation & Anti-Bribery by Chambers and Partners in 2023. Jacky Li has also been ranked as a Rising Star by China Business Law Journal in 2021. He has been ranked by Legalband as a Top 15 recommended lawyer for criminal compliance practice, Top 15 recommended lawyer for compliance practice, and leading lawyer in compliance respectively in 2021, 2022 and 2023.

• PRC SUPREME PROCURATORATE, Expert of Corporate Compliance Third-party Monitorship Committee
• UK Law Certified Expert
• Shanghai Bar Association Law Compliance Committee, Standing Member          
• Association of China Compliance Professionals (ACCP), Director

• 2021-2023 Chambers Anti-corruption: China Law & Practice
• 2019-2022 Legal 500: Bribery & Corruption Annual Review
• 2021-2023 ICLG International Comparative Legal Guide Business Crime
• 2021-2023 Legal Business Research Risk and Compliance  
• 2019-2022 Legal Business Research The International Investigation Review
• 2022 The Guidance Books for Corporate Compliance Practitioner Professional Training, Promotion of International Trade Commercial Legal Service Center
• 2022 Pharmaceutical Industry Compliance Management Practices, China Pharmaceutical Industry Association
• 2023 FAQs: Paths for Personal Information Outbound Transfers (Episode 1)
• 2023 Introduction to the Transitioning Mechanism between Administrative and Criminal Enforcement in Healthcare Industry: From the Perspective of the Measures for the Connection Between Administrative Enforcement and Criminal Justice Related to Medical Products
• 2022 Interpretation on the Newly Revised Administrative Measures on Drug Recalls
• 2022 Legal Issues related to Off-Label Use under PRC and US Laws: Starting from the newly revised PRC Physicians Law
• 2022 Legal compliance in promotional activities in the field of pharmaceutical products - risks and relevant compliance suggestions
• 2021 Cross-Border Compliance Investigation Series | Analysis on Bribe-Taking Parties under the FCPA and China's Anti-Corruption Laws
• 2021 Cross-Border Compliance Investigation Series | How would the Data Security Law Impact Cross-Border Compliance Investigations and Litigations